TX-K2VIEW
K2View , a leading provider of real-time DataOps solutions, today announced its $28 million funding round, which will accelerate the company’s growth and expansion in the emerging DataOps market.
Forestay Capital led the round along with funding from Genesis Partners. It comes on the heels of rapid growth that saw over 75 percent CAGR in revenue, with a strong first half of 2020. This investment will be used to support the company’s go-to-market strategy as it continues its expansion in markets ripe for transformation with DataOps, such as telecom, financial services, healthcare, insurance, logistics and more.
“The fastest method to achieve true agility and exceptional customer experience is moving away from 30-plus years of application-driven enterprise into the data-driven enterprise. This is a critical component for digital transformation and a massive opportunity for us,” said Achi Rotem, CEO and co-founder of K2View. “As we look to the next stage of our growth, our vision is to continue helping companies unlock their potential by providing a faster, better and more cost-effective way to access and control data. To achieve funding of this size in the midst of a worldwide pandemic further proves our business potential. Forestay Capital and Genesis Partners share our vision for the future and are natural partners in helping us accelerate our growth.”
Data, an enterprise’s biggest asset, is siloed in hundreds of different applications and stored in different locations, technologies and structures. In this IT environment, enterprises cannot move fast and provide good customer experience at the same time. K2View’s patented approach and unique architecture deliver the data that enterprises need, exactly how and when they need it —all in real time. Since the launch of its platform in 2015, K2View has proven its vision and technology while helping some of the world’s largest companies tackle complex data challenges.
The platform provides the right data to the right person at the right time in just milliseconds and enables enterprises to operationalize all of their data and get holistic access to what matters the most to their business, while reducing time-to-market from months to weeks.
Changing economic conditions create even greater pressure for IT teams to do more with substantially fewer resources. K2View places efficient, elegant solutions into the hands of its users, delivering in weeks what would take months or years with traditional data management techniques. This helps companies reduce costs substantially while accelerating innovation with challenging use cases such as test data management, customer data hubs and compliance with data privacy regulations.
“As companies undergo digital transformation to adapt to a changing global economy and regulatory environment, K2View’s disruptive technology is transforming the use of data to accelerate business innovation,” said Frederic Wohlwend, Managing Partner at Forestay Capital. “We’re thrilled to partner with this talented and visionary team in their next growth journey and scale the business across the globe to help organizations tackle their most complex data challenges.”
“K2View’s patented solution helps enterprises quickly and cost-effectively achieve a 360-degree, real-time view of data—a challenge that has held back the innovation of enterprise IT,” said Gary Gannot, Managing Partner at Genesis Partners. “The DataOps market has unlimited opportunity and growth potential, and K2View is poised to strengthen its position of leadership as it supports the next wave of market expansion.”
About K2View
K2View is a leading provider of advanced data fabric, data integration, and data delivery software that takes the promise of a 360-degree view of data to the next level. Its flagship solution, K2View Fabric, uses patented logical unit technology to enable quick, easy, and secure access and control to all of an organization’s data, no matter how many different systems and data sources it may have. K2View delivers real-time, holistic access and operational insights to whatever data matters most to organizations in any industry, right when they need it, accelerating transformations in customer experience, cloud enablement, operations, IT modernization, and risk and compliance. Learn more at www.k2view.com and follow us at@k2view .
About Forestay Capital
Founded in 2017, Forestay invests in the tech sector and is focused on innovative, revenue-generating technology companies, in Europe, Israel and the USA, that challenge established models and the status-quo, primarily through software and data. It is part of Waypoint Capital , chaired by Ernesto Bertarelli, which supports a broad portfolio of leading asset management and investment businesses. (www.forestaycapital.com )
About Genesis Partners
Genesis Partners is a leading Israeli venture capital firm with a strong track record and ties to the Israeli entrepreneurs' community and the global technology industry. Its team is composed of venture professionals with extensive experience in venture capital, capital markets, technology, operational management, and entrepreneurship. With over $600M under management, over 100 investments and 38 exits with a current aggregate market value of $22B, Genesis Partners now focuses on growth-stage investments in the information technology and digital transformation sectors. Genesis Partners was founded in 1996 by Eddy Shalev and Dr. Eyal Kishon and joined by Gary Gannot in 2000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200811005246/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
